<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522661</url>
  </required_header>
  <id_info>
    <org_study_id>MUQM1006</org_study_id>
    <nct_id>NCT04522661</nct_id>
  </id_info>
  <brief_title>A Feasibility Randomised Controlled Trial of Early Vitrectomy for Post-operative Exogenous Endophthalmitis</brief_title>
  <acronym>EVIAN</acronym>
  <official_title>Early Vitrectomy and Intravitreal Antibiotics for Post-operative Exogenous Endophthalmitis: A Feasibility Multicentre Randomised Controlled Trial (EVIAN Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Moorfields Eye Hospital NHS Foundation Trust</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomised clinical trial will explore the feasibility and acceptability of carrying out&#xD;
      early vitrectomy surgical treatment compared to standard treatment in acute endophthalmitis.&#xD;
      We will investigate the effectiveness of early vitrectomy plus intravitreal antibiotics&#xD;
      compared to standard care intravitreal antibiotic injections in the management of&#xD;
      postoperative exogenous endophthalmitis. This is a feasibility trial that will evaluate the&#xD;
      expected effect size with which to inform the design of a definitive randomized trial of this&#xD;
      question.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EVIAN Study is a multicentre, feasibility, randomised controlled trial to evaluate the&#xD;
      effect of early vitrectomy surgery on acute endophthalmitis.&#xD;
&#xD;
      Patients with postoperative exogenous endophthalmitis following any ocular&#xD;
      surgery/procedure/injection intervention will be recruited at 48 hours following initial&#xD;
      presentation.&#xD;
&#xD;
      Patients with vision of 35 ETDRS letters or better are ineligible for the trial, and would&#xD;
      continue on standard of care management. Patients with vision of worse than 35 ETDRS letters&#xD;
      will be eligible for the study. At the 48-hour time-point, eligible patients will be&#xD;
      randomised in a 1:1 ratio.&#xD;
&#xD;
      The treatment group will undergo vitrectomy within 48 hours of randomisation. The control&#xD;
      group will have continued intravitreal antibiotic eye injections according to local&#xD;
      protocols. If the vision reaches perception of light, then a vitrectomy surgery would be&#xD;
      considered as part of standard of care at 12-15 days. Follow up will be for 6 months in both&#xD;
      groups.&#xD;
&#xD;
      Visual acuity, funds photography, B-scan ultrasound, and optical coherence tomography (OCT)&#xD;
      scanning will be performed from baseline until the final follow-up at 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 12, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised control trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient recruitment</measure>
    <time_frame>Trial study period (Week 1 to Week 104)</time_frame>
    <description>Number of participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distance Best Corrected Visual Acuity change from baseline</measure>
    <time_frame>Trial study period (Week 1 to Week 24)</time_frame>
    <description>Early Treatment Diabetic Retinopathy Study (ETDRS) letters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Endophthalmitis Postoperative Acute</condition>
  <arm_group>
    <arm_group_label>Early Vitrectomy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitrectomy surgery plus intravitreal antibiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vitrectomy</intervention_name>
    <description>Vitrectomy within 48 hours of randomisation</description>
    <arm_group_label>Early Vitrectomy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravitreal antibiotics</intervention_name>
    <description>Intravitreal Antibiotics at 48 hours</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Early Vitrectomy Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient over 18 years of age&#xD;
&#xD;
          2. Patient has capacity to give informed consent&#xD;
&#xD;
          3. Patient has not previously been enrolled in this study in regards to their other eye&#xD;
&#xD;
          4. Diagnosis of postoperative endophthalmitis within 6 weeks of ocular&#xD;
             surgery/procedure/injection&#xD;
&#xD;
          5. Best corrected visual acuity worse than 35 ETDRS letters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient suffered a major thromboembolic event within the past 3 months as (defined as&#xD;
             transient ischaemic attack, Stroke, or myocardial infarction)&#xD;
&#xD;
          2. Patient has major surgery planned over the next 12 months defined as requiring general&#xD;
             anaesthesia or reduced mobilisation&#xD;
&#xD;
          3. Known adverse reaction to intravitreal antibiotics&#xD;
             (amikacin/vancomycin/cephalosporins)&#xD;
&#xD;
          4. Blood pressure greater than 200 systolic or 100 diastolic&#xD;
&#xD;
          5. Any other condition that in the opinion of the investigator would preclude&#xD;
             participation in the study (such as unstable medical status or severe disease that&#xD;
             would make it difficult for the patient to be able to complete the study)&#xD;
&#xD;
          6. The patient will use an investigational drug during the study&#xD;
&#xD;
          7. History of optic atrophy in the study eye&#xD;
&#xD;
          8. Corneal oedema/haze that would prevent visualisation of fundus to perform vitrectomy&#xD;
             surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahi MK Muqit, PhD FRCOphth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moorfields Eye Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol. 1995 Dec;113(12):1479-96.</citation>
    <PMID>7487614</PMID>
  </results_reference>
  <results_reference>
    <citation>Negretti GS, Chan W, Pavesio C, Muqit MMK. Vitrectomy for endophthalmitis: 5-year study of outcomes and complications. BMJ Open Ophthalmol. 2020 Mar 24;5(1):e000423. doi: 10.1136/bmjophth-2019-000423. eCollection 2020.</citation>
    <PMID>32258421</PMID>
  </results_reference>
  <results_reference>
    <citation>Busbee BG, Recchia FM, Kaiser R, Nagra P, Rosenblatt B, Pearlman RB. Bleb-associated endophthalmitis: clinical characteristics and visual outcomes. Ophthalmology. 2004 Aug;111(8):1495-503; discussion 1503.</citation>
    <PMID>15288977</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitrectomy</keyword>
  <keyword>intravitreal antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endophthalmitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results to be reported in an International Committee of Medical Journal Editors journal after deidentification (text, tables, figures, and appendices)</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. The access should only be for individual participant data meta-analysis.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

